GLP-1 medications: separating clinical fact from TikTok hype

What did @rajamohanmd actually say?

Nothing about GLP-1 medications. Genuinely nothing. The transcript is a rap or spoken word performance, and it contains zero medical content. Lines like "Blindfold on me, I still got the most vision" and "big fish catching me, they gon' need a bigger boat" are motivational boasts, not clinical statements. There is no mention of semaglutide, tirzepatide, weight loss, blood sugar, or any health topic whatsoever.

The video was tagged under the GLP-1 category, which is why it landed here for review. But the content itself is a confidence-driven lyrical piece, apparently in the style of a self-promotional rap. The word "Transceder" appears repeatedly and seems to function as either a personal brand name or an alter ego. Peter Piper picked peppers. That is the level of medical density we are working with here.

There is nothing to quote in context of health claims because no health claims were made.

Does the science back this up?

There is no science to apply here. The transcript does not make a single verifiable health claim, so there is nothing to confirm or refute with clinical literature. This is genuinely rare in the GLP-1 content space, where misinformation tends to run at a high clip.

For the record, the current evidence base for GLP-1 receptor agonists is substantial. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide producing up to 22.5% body weight reduction at 72 weeks. The STEP 1 trial (Wilding et al., 2021, NEJM) demonstrated semaglutide at 2.4mg producing approximately 14.9% weight loss versus 2.4% with placebo. None of this is relevant to what was said in the video, but it seems worth noting given the platform context and the size of the audience that found this content.

What did they get wrong (or right)?

This is an unusual position to be in. There are no medical claims to evaluate as wrong or right. The creator did not misinform anyone about GLP-1 dosing, did not compare compounded peptides to brand-name drugs, did not suggest these medications cure any disease, and did not recommend any drug combinations. From a strict medical misinformation standpoint, this video is clean, if only by omission.

What is worth flagging is the category mismatch. Nearly 439,000 people viewed a video tagged as GLP-1 content that has no GLP-1 content. Whether that tagging was intentional for algorithmic reach or accidental is unclear. Viewers searching for weight loss medication information who found this video got nothing harmful, but they also got nothing useful. That is a lesser problem than spreading dangerous dosing advice, but it contributes to noise in a content ecosystem that already struggles with signal quality.

What should you actually know?

If you landed on this video looking for reliable information about GLP-1 medications, here is what actually matters. These are prescription medications with real clinical evidence behind them, and they require medical supervision. Semaglutide and tirzepatide work by mimicking hormones that regulate appetite and blood sugar. They are not magic, and they do not work the same way for every person.

Side effects are real and common. Nausea, vomiting, and gastrointestinal discomfort affect a significant portion of users, particularly during dose escalation. The SELECT trial (Lincoff et al., 2023, NEJM) added cardiovascular outcome data showing semaglutide reduced major cardiovascular events in adults with obesity, which expanded the conversation around these drugs beyond just weight loss.

Compounded versions of these medications are not the same as FDA-approved brand-name products. The formulations, excipients, and quality controls differ. Anyone considering a GLP-1 therapy should be working with a licensed clinician, not making decisions based on social media content, including content that is actually about something else entirely.